Emerging Growth Research Releases Q2:26 Quarterly Update on SBC Medical Group; Reiterates Buy Rating and Increases Price Target to $11.00
Rhea-AI Summary
Emerging Growth Research released its Q2:26 update on SBC Medical Group (NASDAQ:SBC), reiterating a Buy rating and raising its 12‑month price target from $10.00 to $11.00. The firm highlights SBC’s return to revenue growth after 2025 pricing-related headwinds and franchise fee reductions.
Q2:26 revenue rose about 13% year-over-year to $49.2 million, with income from operations up roughly 30% to $19.0 million. Net income from continuing operations increased to $10.7 million from $2.4 million, and Adjusted EBITDA grew to $19.7 million from $15.3 million.
SBC’s clinic network reached 287 clinics, up 34 locations (≈13%) year-over-year, serving about 6.9 million annual visits with a 73% repeat rate. The company ended Q2:26 with approximately $185 million in cash and $38 million in commercial bank loans, implying net cash of about $147 million. According to Emerging Growth Research, SBC is expanding internationally, pursuing AI-driven initiatives that management expects could add up to $15 million in annual revenue, and trades at a discount to the firm’s DCF-derived valuation of roughly $10.66 per share.
Positive
- Revenue +13% YoY to $49.2M in Q2:26 from $43.4M
- Income from operations +30% YoY to $19.0M from $14.6M
- Net income from continuing operations rose to $10.7M from $2.4M
- Adjusted EBITDA increased to $19.7M from $15.3M
- Clinic network +34 locations to 287; visits 6.9M with 73% repeat
- Net cash ≈$147M with $185M cash and $38M bank loans
- Buy rating reiterated with raised 12‑month price target to $11.00
Negative
- Prior-year 2025 revenue decline tied to pricing-related headwinds and franchise fee reduction
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Q2 earnings report | Positive | +0.0% | Revenue and earnings growth were reported, but the recorded 24-hour reaction was 0%. |
| Aug 03 | Earnings date notice | Neutral | +3.3% | The company scheduled its second-quarter results and conference call for August 13. |
| Jul 08 | Clinic launch | Positive | +0.3% | SBC announced Japan's first specialized men's beard hair-removal clinic. |
| May 26 | Investor conferences | Neutral | +1.6% | The company announced participation in multiple upcoming investor conferences. |
| May 22 | Clinic expansion | Positive | -1.0% | SBC and BLEZ ASIA announced a new aesthetic dermatology section in Bangkok. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the supplied recent events, positive or informational announcements were followed by reactions ranging from -0.97% to +3.27%, with one 0% result; no consistent direction was shown.
Key Terms
adjusted ebitda financial
net cash financial
public float financial
dcf financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Emerging Growth Research today announced the release of its Q2:26 Quarterly Update Report on SBC Medical Group Holdings (NASDAQ:SBC), reiterating its Buy rating and increasing its 12-month price target to
The Quarterly Update highlights SBC Medical Group's return to revenue growth in 2026 following the completion of pricing-related headwinds experienced during 2025, while emphasizing the Company's strong cash position, expanding clinic footprint, continued international expansion, and new AI-driven growth initiatives. Emerging Growth Research believes the Company is positioned for renewed growth following the 2025 revenue decline and remains significantly undervalued relative to its long-term earnings potential.
Key Highlights from the Q2:26 Quarterly Update:
Revenue Growth Returns: Q2:26 revenue increased approximately
Income from Operations and Earnings Improve: Q2:26 income from operations increased approximately
AI Provides Additional Growth Potential: Management expects AI initiatives implemented at the clinic level to generate up to
Continued Clinic Expansion: SBC's clinic network increased by 34 locations year-over-year, or approximately
Strong Cash Position: SBC ended Q2:26 with approximately
International Expansion and New Growth Initiatives: SBC continues to pursue opportunities in Japan, Southeast Asia, and the United States, while developing AI-driven operational initiatives and its Wellness 2.0/Longevity strategy. The Company has also expanded internationally through acquisitions, partnerships, and investments.
Improved Trading Liquidity: Emerging Growth Research notes that SBC has taken steps to increase its public float, including becoming a Russell 3000 company and partially reducing the founder's ownership position, which management believes should improve trading liquidity over time.
Attractive Valuation: At the August 21, 2026 closing price of
Buy Rating Reiterated: Emerging Growth Research remains bullish on SBC Medical Group and believes the Company's renewed revenue growth, strong operating margins, substantial net cash position, clinic expansion, AI initiatives, and potential international M&A provide significant long-term upside. The research firm therefore reiterates its Buy rating and increases its 12-month price target to
For a copy of the full Q2:26 Quarterly Update Report, please visit:
https://storage.googleapis.com/accesswire/media/1211337/sbcq226quarterly-update-082426.pdf
or
https://www.emerginggrowth.com/profile/sbc/ (on the right side of the page as you scroll down)
About SBC Medical Group Holdings Incorporated: SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, Hair Loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose, "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
About Emerging Growth Research
Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including quarterly updates and flash reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.
Contact:
Emerging Growth Research
Research@EmergingGrowth.com
www.emerginggrowth.com
Forward-Looking Statements
This press release contains forward-looking statements concerning business operations, financial performance, growth initiatives, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
SOURCE: SBC Medical Group Holdings Incorporated
View the original press release on ACCESS Newswire